Superluminal Medicines, Inc.
Filings
| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2026-09-039/3/26 | New | $65,480,796 | $65,480,796 | Equity Only | 06b | SEC linkSEC |
| 2025-08-268/26/25 | New | $5,000,000 | Unknown | Debt Only | SEC linkSEC | |
| 2024-09-049/4/24 | New | $20,041,660 | $20,041,660 | Equity Only | 06b | SEC linkSEC |
| 2023-08-288/28/23 | New | $25,679,107 | $25,679,107 | Equity Only | 06b | SEC linkSEC |
Directors and Executives (Current and Past)
| Name | Role |
|---|---|
| Cony D'cruz | Director, Executive, Promoter |
| Andrew Levin | Director |
| Dylan Morris | Director |
| Harsha Paladugu | Director |
| Craig Randall | Executive |
| Catherine Riesen | Executive |
| Nandita Shangari | Director |
| Diamantis Xylas | Director |
Industry: Biotechnology (See others in industry)
Address:
15 Necco St. Lilly Gateway Labs, 4 Th Floor
Boston, MA, 02110
Phone: (301) 525-8752
Boston, MA, 02110
Phone: (301) 525-8752